The figures are in: HealthCare.gov has about 6.4 million paying customers who are at risk of losing subsidies in a pending Supreme Court case.» Read More
While a big court decision threatens billions in Obamacare subsidies, many people who benefit from that money are unaware they even get it.
A new hepatitis drug could be significant for Arrowhead Research, CEO Chris Anzalone says.
Slower growth in healthcare spending is shoring up the funding outlook for the federal Medicare program that covers hospital bills for the elderly.
Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.
Reckitt Benckiser plans to spin off its heroin-addiction treatment in the next 12 months as sales slide under pressure from rival versions.
Hospira could use an acquisition of the Danone business to redomicle its tax headquarters in France in a deal known as a tax inversion.
Additional rules and enforcement from federal agencies have a majority of employers worried about how to run their firms.
Big variations in price from provider to provider could be adding to your bills—even if you're insured.
Surely Congress didn't mean to include a "poison pill" for the Affordable Care Act when it passed it, says law professor Tim Jost.
States might need to spend only hundreds of dollars or less to protect Obamacare subsidies for residents currently enrolled in HealthCare.gov plans.
GlaxoSmithKline faces new corruption allegations in Syria, where it has been accused of paying bribes to secure business.
CRE, one of the worst of the superbugs, is spreading in some hospitals, and there's worry that cases are under-reported.
A Liberian man is being tested for the deadly Ebola virus in Nigeria's commercial capital of Lagos, a megacity of 21 million people.
The federal government says 10.3 million adults have become newly insured since the launch of Obamacare last fall.
Roche confirmed its full-year outlook, but posted profit that missed expectations following an impairment charge at its diagnostics business.
Gilead Sciences delivered quarterly earnings and revenue that topped analysts' expectations on Wednesday.
When Senate Majority Leader Harry Reid went "nuclear" last winter, he just might have saved a major part of Obamacare from a huge challenge it faces.
U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.
After a split ruling on Obamacare from the courts, who gets the last word? Law professor Dan Eaton weighs in.
Puma Biotechnology's experimental breast cancer drug met its main goal in a late-stage trial, but the options market is sensing something funky.
Get the best of CNBC in your inbox